{
    "clinical_study": {
        "@rank": "18359", 
        "arm_group": {
            "arm_group_label": "Japanese encephaltis chimerix vaccine", 
            "arm_group_type": "No Intervention", 
            "description": "This is a single-arm study. Japanese encephalitis chimeric vaccine (JECV) will be administered to all subjects and check for antibody response 4 weeks after vaccination."
        }, 
        "brief_summary": {
            "textblock": "This study has aim to describe the immune response to the second dose of Japanese\n      encephalitis chimeric vaccine (JECV) in children previously vaccinated with one dose of JECV\n      5 years ago."
        }, 
        "brief_title": "Antibody Response of a Boosted Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Japanese Encephalitis", 
        "condition_browse": {
            "mesh_term": [
                "Encephalitis", 
                "Encephalitis, Japanese"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a prospective study to demonstrate the boosting antibody response in children\n      previously vaccinated with one dose of JECV 5 years ago."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Subject who was vaccinated with 1 dose JE-CV in JEC02 and participated in 5 year\n             follow-up in JEC05 trial and finished year 5 of follow-up.\n\n          2. Provision of Informed Consent Form signed by at least one parent or other legally\n             acceptable representative.\n\n          3. Subject and parent/legally acceptable representative or guardian able to attend all\n             scheduled visits and to comply with all trial procedures\n\n          4. In good general health, based on medical history and physical examination\n\n        Exclusion Criteria:\n\n          1. Participation in another clinical trial investigating a vaccine which need to have\n             vaccination or blood draw within the 4 weeks preceding the trial vaccination except\n             JEC05\n\n          2. Planned participation in another clinical trial during the Day0-Day28 period\n\n          3. Receipt of live vaccine within 4 weeks preceding the trial vaccination\n\n          4. Planned receipt of any vaccine in the 4 weeks following the trial vaccination\n\n          5. Receipt of blood or blood-derived products in the past 3 months, which might\n             interfere with assessment of the immune response\n\n          6. Known systemic hypersensitivity to any of the vaccine components, or history of a\n             life-threatening reaction to the vaccine used in the trial or to a vaccine containing\n             any of the same substances\n\n          7. Chronic illness or any underlying illness that, in the opinion of the investigator,\n             is at a stage where it might interfere with trial conduct or completion"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "80 Months", 
            "minimum_age": "72 Months"
        }, 
        "enrollment": {
            "#text": "88", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01954810", 
            "org_study_id": "JEC24"
        }, 
        "intervention": {
            "arm_group_label": "Japanese encephaltis chimerix vaccine", 
            "description": "Japanese encephalitis chimeric vaccine (JECV)will be administered to every children in the study for one dose and check for antibody response 4 weeks after vaccination", 
            "intervention_name": "Japanese encephalitis chimeric vaccine (JECV)", 
            "intervention_type": "Biological", 
            "other_name": "IMOJEV"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Antibodies", 
                "Immunoglobulins"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "JECV", 
            "IMOJEV", 
            "Booster response", 
            "Children", 
            "antibody response", 
            "Duration"
        ], 
        "lastchanged_date": "October 6, 2013", 
        "location": {
            "contact": {
                "email": "suraponwiangnon@gmail.com", 
                "last_name": "Surapon Wiangnon, M.D.", 
                "phone": "+66-43-348382"
            }, 
            "facility": {
                "address": {
                    "city": "Muang", 
                    "country": "Thailand", 
                    "state": "Khon Kaen", 
                    "zip": "40002"
                }, 
                "name": "Department of Pediatrics, Faculty of Medicine, Khon Kaen University"
            }, 
            "investigator": {
                "last_name": "Pope Kosalaraksa, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Thailand"
        }, 
        "number_of_arms": "1", 
        "official_title": "Assessment of Antibody Response of a Boosted Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With a Single Dose of JE-CV", 
        "overall_contact": {
            "email": "pkosalaraksa@yahoo.com", 
            "last_name": "Pope Kosalaraksa, M.D.", 
            "phone": "+66-89-7112236"
        }, 
        "overall_official": {
            "affiliation": "Khon Kaen University", 
            "last_name": "Pope Kosalaraksa, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Thailand: Food and Drug Administration", 
                "Thailand: Ethical Committee"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Neutralizing antibody titers before JECV booster (on D0), and after IMOJEV booster (on D28)", 
            "measure": "Neutralizing antibody titers after JECV vaccination", 
            "safety_issue": "Yes", 
            "time_frame": "28 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01954810"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Khon Kaen University", 
            "investigator_full_name": "Pope Kosalaraksa", 
            "investigator_title": "Associate Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Khon Kaen University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Khon Kaen University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}